Fosphenytoin
Brain Ischemia
Floatz Rating
B58/100
Confidence
Indicative
Sponsor
University of North Carolina, Chapel Hill
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06081283CT.gov Antiseizure Medication in Seizure Networks at Early Acute Brain Injury | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Ischemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fosphenytoin (this asset) | University of North Carolina, Chapel Hill | Approved | B · 58 |
| Dipyridamole | UMC Utrecht | P4 | BB |
| Aspirin | City Clinical Hospital No. 67, Moscow, Russia | P4 | BB |
| Sovateltide | Pharmazz, Inc. | P3 | BB |
| Probucol | Asan Medical Center | P4 | BB |
| Cilostazol | Asan Medical Center | P4 | BB |
| Lacosamide | University of North Carolina, Chapel Hill | P4 | BB |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Valproic Acid | University of North Carolina, Chapel Hill | P4 | BB |
+28 more in the Brain Ischemia cohort
Other indications for Fosphenytoin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy With Generalized Tonic-Clonic Seizures | — | P4 | B · 61 |
| Traumatic Brain Injury | — | P4 | B · 58 |
| Brain Hypoxia - Ischemia | — | P4 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fosphenytoin in Brain Ischemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fosphenytoin-brain-ischemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →